According to Axis Securities, the reduction in reciprocal taxes is incrementally positive for Indian pharmaceutical companies, particularly those with significant exposure to the US market, ...

Finance Minister Nirmala Sitharaman, during her ninth consecutive Budget speech, announced an outlay of ₹10,000 crore under ...

Biocon Ltd is quoting at Rs 373.85, up 0.42% on the day as on 12:44 IST on the NSE. The stock is down 4.2% in last one year as compared to a 8.62% gain in NIFTY and a 1.45% gain in the Nifty Pharma.

Pharma major Biocon is set to announce its Q3FY26 results on 12 Feb 2026. Brokerage reports project a strong Q3FY26 for Biocon, driven by robust momentum across biosimilars and generics.

In the equity market, the 30-share BSE Sensex traded 281.75 points higher at 82,532.68. The 50-share NSE Nifty edged higher by 61.10 points to 25,376.05. She also proposed interventions in six areas, ...

S&P Global Ratings has upgraded the long-term issuer credit rating of Biocon Biologics Limited to 'BB+' from 'BB' and revised ...

Sitagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes. The Food and Drug Administration has given Biocon Ltd.’s wholly owned ...

By Bharath Rajeswaran Feb 1 (Reuters) - Indian benchmarks held on to modest gains in a special trading session on Sunday as ...

Utah-based Civica will begin selling a type of long-acting insulin on Jan. 1, 2026, although it will not come from the nonprofit drug maker’s Petersburg facility. Civica announced Thursday it has ...

The strategy will include a biopharma-focused network with three new National Institutes of Pharmaceutical Education and ...